SCHEMBL5946366

SCHEMBL5946366

CCOC(=O)CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.65
LMNA P02545 2/20 0.65
CYP1A2 P05177 2/20 0.65
CYP3A4 P08684 2/20 0.65
CYP2D6 P10635 2/20 0.65
PMP22 Q01453 2/20 0.65
KMT2A Q03164 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
ABCB11 O95342 1/20 0.65
CYP2C9 P11712 1/20 0.65
BLM P54132 1/20 0.65
HRH4 Q9H3N8 8/20 0.63
HRH1 P35367 6/20 0.63
HTR2A P28223 6/20 0.63
HTR2C P28335 5/20 0.63
DRD2 P14416 4/20 0.63
DRD4 P21917 4/20 0.63
DRD3 P35462 4/20 0.63
HRH2 P25021 3/20 0.63
CHRM1 P11229 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5946431 0.91 MEN1 (0.68) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946367 0.89 MEN1 (0.66) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946381 0.88 MEN1 (0.65) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946361 0.88 MEN1 (0.64) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946405 0.87 MEN1 (0.68) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946357 0.86 MEN1 (0.74) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946391 0.82 DRD2 (0.64) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL8204135 0.82 MEN1 (0.63) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5946392 0.81 MEN1 (0.81) MEN1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL10194037 0.80 HTR2C (0.79) MEN1LMNACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063754-A1 Methods of treating a sleep disorder HYPNION, INC. 2006-03-23 US disclosed
EP-0447857-B1 A polycyclic compound, method for preparing the same, and pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL (JP) 1994-12-14 EP disclosed
US-5344828-A Antiallergens; bronchial asthma HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1994-09-06 US disclosed
EP-0447857-A1 A polycyclic compound, method for preparing the same, and pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063754-A1 Methods of treating a sleep disorder HCRTR2, HCRTR1, CHAT MEN1 3844/4885LMNA 1582/4885CYP1A2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.